Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.60 USD
Change Today +0.12 / 1.27%
Volume 654.4K
MDXG On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1775 West Oak Commons Court, NE

Marietta, GA 30062

United States

Phone: 770-651-9100

Fax:

MiMedx Group, Inc. operates as a developer, manufacturer, and marketer of patent-protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. The company’s biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births could elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. The company processes the human amniotic membrane utilizing its proprietary Purion Process, to produce an implant, which is referred to as an ‘allograft’. Technology and Products AmnioFix, EpiFix, and Other Tissue -Based Allografts The company is the major supplier of amniotic tissue, having supplied approximately 350,000 allografts (as of December 31, 2014) for application in the wound care, surgical, sports medicine, ophthalmic, and dental sectors of healthcare. The company’s tissue-based products include its own brands, AmnioFix and EpiFix, as well as products that the company supplies on a private label or ‘OEM’ basis. Tissue Processing and Recovery The company operates a licensed tissue bank that is registered as a tissue establishment with the United States Food and Drug Administration (FDA). The company is an accredited member of the American Association of Tissue Banks. The company partners with physicians and hospitals to recover donated placental tissue. The company’s processing technique primarily focuses on preserving the tissue’s bioactive growth factor content, and maintaining the structure and collagen matrix of the tissue. The Purion Process also allows the allograft to be stored at room temperature and have a five-year shelf life. Additionally, each sheet allograft incorporates specialized visual embossments that assist the health care practitioner with proper allograft placement and orientation. EpiFix The company’s EpiFix allograft is configured for external use. It is used to improve healing of wounds, as well as to reduce inflammation and scarring. EpiFix and EpiFix Particulate have been used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds (such as wounds following plastic surgery). The company offers EpiFix in a sheet form, as well as a particulate powder form. The powder could be packed into wounds and is particularly useful for tunneling wounds. Some physicians also choose to mix the powder with saline to inject it into the wound bed and wound margins. AmnioFix The company’s AmnioFix allografts are configured for internal use. Its AmnioFix product line consists of three configurations, such as AmnioFix, AmnioFix Wrap, and AmnioFix Injectable: AmnioFix is provided in a sheet form. It is used to reduce inflammation, improve soft tissue healing and to minimize scar tissue formation. It has been used in spine, urology and general surgeries. AmnioFix Wrap also is supplied in a sheet form and is configured for the same purposes as AmnioFix, but is optimized for use as a ‘wrap’ for nerves, tendons, or ligaments. AmnioFix Injectable is supplied in micronized powder form used for injection into soft tissue areas. AmnioFix Injectable is used to reduce inflammation while improving healing of soft tissue. AmnioFix Injectable has been used to treat conditions, such as tendonitis, including plantar fasciitis, lateral epicondylitis, and medial epicondylitis, bursitis, strains, and sprains. Other Tissue Products Allografts for ophthalmic surgery and dental applications are sold on an OEM basis pursuant to agreements whereby the company has granted third parties exclusive licenses to some of its technology for use in those fields in specified markets. The company also sells products on a non-exclusive OEM basis to Medtronic for spinal procedures and Zimmer for spine and orthopedic procedures. Medical Device Technologies- CollaFix and HydroFix CollaFix The company’s CollaFix technology combines a means of creating fibers from solu

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDXG:US $9.60 USD +0.12

MDXG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliqua BioMedical Inc $4.40 USD +0.11
Derma Sciences Inc $5.93 USD +0.02
Medtronic PLC $73.56 USD +0.04
Osiris Therapeutics Inc $18.73 USD +0.59
Smith & Nephew PLC 1,163 GBp +29.00
View Industry Companies
 

Industry Analysis

MDXG

Industry Average

Valuation MDXG Industry Range
Price/Earnings 66.1x
Price/Sales 6.4x
Price/Book 11.2x
Price/Cash Flow 58.2x
TEV/Sales 6.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MIMEDX GROUP INC, please visit www.mimedx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.